Clinical Trials & Research

Interview conducted by Emily Henderson, B.Sc.Aug 18 2020 Thought LeadersDr. Keith FargoDirector of Scientific Programs & OutreachAlzheimer’s AssociationNews-Medical speaks to Dr. Keith Fargo from the Alzheimer’s association about their latest research which looked at risk factors that could aid in the early detection of Alzheimer’s disease. Why is it important to research Alzheimer’s and its

Print this page SAN FRANCISCO, CA Aug 3, 2020 – Today, members of the COVID R&D Alliance AbbVie, Inc. (NYSE: ABBV), Amgen Inc. (NASDAQ: AMGN), and Takeda Pharmaceutical Co. Ltd. (NYSE: TAK) announced the first patients enrolled in the I-SPY COVID Trial (Investigation of Serial Studies to Predict Your COVID Therapeutic Response with Biomarker Integration and

Reviewed by Emily Henderson, B.Sc.Aug 15 2020 The intensive implementation of currently available tools to fight malaria can achieve a drastic reduction in disease burden, but is not enough to interrupt its transmission. This is the main conclusion reached by the Mozambican Alliance Towards Elimination of Malaria (MALTEM), coordinated by the Barcelona Institute for Global

Print this page CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aug. 11, 2020– Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that the U.S. government has secured 100 million doses of mRNA-1273 as part of the U.S. government’s goal of securing early access to safe and effective

As the COVID-19 pandemic continues to take thousands of lives every day in different parts of the world, vaccine and antiviral research is continuing, as the only hope of emergence from under the shadow of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, a recent study by researcher Bhavin S Khatri at Imperial College London

Print this page NEW YORK and MAINZ, GERMANY, August 12, 2020 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that preliminary, peer-reviewed data from their BNT162 mRNA-based vaccine development program, Project Lightspeed, against SARS-CoV-2, were published online in the journal Nature. These preliminary clinical data on BNT162b1, a nucleoside-modified messenger RNA (modRNA) candidate that encodes an optimized

A research team from the National University of Singapore (NUS) has identified a new avenue to maintain bone health while reducing bone resorption. The work, led by Associate Professor Christoph Winkler from the Department of Biological Sciences at the NUS Faculty of Science, opens up new and potentially more effective osteoporosis treatments. Osteoporosis is the

Print this page SOUTH SAN FRANCISCO, Calif., Aug. 10, 2020 (GLOBE NEWSWIRE) – Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that its COVID-19 Investigational New Drug (IND) application has been filed with the US Food and Drug Administration (FDA). “We are very excited to reach this

In many cases, a complex interplay between our genes and the environment governs whether or not we will develop a certain disease. Interestingly though, researchers are discovering that the genetic component of disease predisposition may depend on our ethnic background. In a study published recently in Annals of the Rheumatic Diseases, a team of researchers

Print this page GAITHERSBURG, Md., Aug. 04, 2020 (GLOBE NEWSWIRE) – Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced Phase 1 data from its Phase 1/2 randomized, observer-blinded, placebo-controlled trial of its COVID‑19 vaccine with and without Matrix‑M™ adjuvant in healthy adults 18-59 years of age. NVX‑CoV2373, the Company’s recombinant

By conducting advanced analyses of immune system activation in patients with severe COVID-19, researchers at Karolinska Institutet have managed to identify several cell types that play a key part in the immune response to the new coronavirus and the hyperinflammation seen in severe cases of the disease. The results are published in the scientific journal

Print this page MORRISTOWN, N.J., Aug. 05, 2020 (GLOBE NEWSWIRE) — BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory and degenerative diseases through a portfolio built around gelsolin technology, announced today that it enrolled its first patient in its Phase 2 study of hospitalized patients with severe COVID-19 pneumonia. This

Aug 6 2020 ZOSI Analytical, LLC, a hemp analytical testing laboratory in Central Texas, has announced it has received its Drug Enforcement Agency (DEA) registration to handle Schedule 1 substances. This is the first of its type issued in the State of Texas and was issued in support of Federal and State guidelines regarding oversight

Print this page San Francisco, CA and Covington, KY, August 4, 2020 — Angion Biomedica Corp. (Angion), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases, and CTI Clinical Trial and Consulting Services (CTI), a leading contract research organization, announced enrollment of the

Vitamin B12 is an essential micronutrient that is needed for functions such as maintaining the nervous system and forming blood cells. However, B12 is mainly found in food of animal origin. Those who consume only small amounts of animal products or are vegan must, therefore, take B12 in the form of pills or eat food

Print this page NEW BRUNSWICK, N.J., July 30, 2020 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced that its lead vaccine candidate protected against infection with SARS-CoV-2, the virus that causes COVID-19, in pre-clinical studies. The data, published in Nature, show the Company’s investigational adenovirus serotype 26 (Ad26) vector-based vaccine elicited a robust immune response as

Reviewed by Emily Henderson, B.Sc.Aug 1 2020 The Emergency Committee on COVID-19, convened by the WHO Director-General under the International Health Regulations (2005) (IHR), held its fourth meeting on 31 July. In its statement following the meeting, published today, it expressed “appreciation for WHO and partners’ COVID-19 pandemic response efforts, and highlighted the anticipated lengthy

Print this page 30 July 2020 — Nirsevimab showed a significant reduction in medically-attended lower respiratory tract infections (LRTI) and hospitalisations caused by respiratory syncytial virus (RSV) in healthy preterm infants in a positive Phase IIb trial published in the New England Journal of Medicine. The trial demonstrated for the first time that a single-dose

According to researchers from The University of Texas MD Anderson Cancer Center, the implementation of social distancing policies corresponded with significant reductions in transmission of the SARS-CoV-2 virus and reduced community mobility, both in the U.S. and globally, providing evidence that social distancing is a useful tool in preventing further spread of COVID-19. The study,

Print this page NEW YORK & MAINZ, Germany–(BUSINESS WIRE) July 27, 2020 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the start of a global (except for China) Phase 2/3 safety and efficacy clinical study to evaluate a single nucleoside-modified messenger RNA (modRNA) candidate from their BNT162 mRNA-based vaccine program against

Jul 29 2020 Design Space InPharmatics (DSI), a Regulatory Drug Development Consulting Firm provides Chemistry, Manufacturing and Controls (CMC) regulatory, technical, and project management consulting services to healthcare product companies that manufacture and/or market pharmaceuticals, biopharmaceuticals, and and gene therapy products. Since 2007 DSI has provided clients and sponsors with innovative strategies and exceptional quality

Print this page CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jul. 27, 2020– Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that the Phase 3 study of its mRNA vaccine candidate (mRNA-1273) against COVID-19 has begun dosing participants. The Phase 3

Existing limited evidence suggests that wearing face coverings to protect against COVID-19 does not lead to a false sense of security and is unlikely to increase the risk of infection through wearers foregoing other behaviours such as good hand hygiene, say researchers from the University of Cambridge and King’s College London. Writing in BMJ Analysis,

Print this page SAN DIEGO, CA and TAICANG, SUZHOU, China – July 20, 2020 – Connect Biopharma, a clinical-stage biopharmaceutical company focused on identifying and developing potent and specific immune modulating molecules today announced that the first patient has been dosed in a Phase 2 clinical trial of CBP-201 for the treatment of moderate-to-severe atopic

Reviewed by Emily Henderson, B.Sc.Jul 24 2020 Early and accurate detection is critical for preventing the spread of COVID-19 and providing appropriate care for patients. Nasopharyngeal (NP) swabs, which require inserting a long shaft into the nasal cavity to collect a sample from the back of the nose and throat, are currently the gold standard

Print this page 20 July 2020 –  Interim results from the ongoing Phase I/II COV001 trial, led by Oxford University, showed AZD1222 was tolerated and generated robust immune responses against the SARS-CoV-2 virus in all evaluated participants. COV001 is a blinded, multi-centre, randomised controlled Phase I/II trial with 1,077 healthy adult participants, aged 18-55 years.

Reviewed by Emily Henderson, B.Sc.Jul 22 2020 Arcturus Therapeutics Holdings Inc., a leading clinical-stage messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases and vaccines, and Duke-NUS Medical School, Singapore’s flagship research-intensive graduate entry medical school, today announced that the Clinical Trial Application for COVID-19 vaccine candidate LUNAR-COV19

Print this page LEXINGTON, Mass.–(BUSINESS WIRE)–Jul. 7, 2020– Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases, today announced development plans to support a New Drug Application (NDA) for the novel investigational reactive aldehyde species (RASP) inhibitor